Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients

Insights and discussion from the cutting edge with reference to journal articles and other research papers.
Post Reply
User avatar
SusanJ
Senior Contributor
Senior Contributor
Posts: 3058
Joined: Wed Oct 30, 2013 7:33 am
Location: Western Colorado

Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients

Post by SusanJ »

We've talked about mis-folded proteins in the past. This one looks interesting, albeit still in the early stages.
The target of PTI-125 is an altered form of filamin A (FLNA), a scaffolding protein. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. Cassava’s lead drug candidate, PTI-125, is a small molecule drug that restores the normal shape of FLNA in the brain. This action improves the function of certain receptors in the brain and exerts powerful anti-neuroinflammatory effects.
https://www.cassavasciences.com/news-re ... al-results

Don't have time to dig any further, like if there were any E4's in their first set of patients, or will be in the next set.
Post Reply